Rabbit PDGF Receptor Activation Sampler Kit Polyclonal Antibody

Inquiry

Cat. No.: DAB-0012403

Size: 20 µL Size: 100 µL Size: Customer Size

Product Information
Clonality	Polyclonal
Host Species	Rabbit
Product Description	Polyclonal antibodies are produced by immunizing animals with synthetic phosphopeptides corresponding to residues surrounding Tyr542 of human SHP-2 protein. Polyclonal antibodies are purified by protein A and peptide affinity chromatography. Monoclonal activation state antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Ser473 of human Akt, Thr202/Tyr204 of human p44 MAP kinase, or Tyr751 of human PDGF receptor β. Monoclonal control antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues in the carboxy-terminal sequence of mouse Akt, the carboxy terminus of rat p44 MAP kinase, the carboxy-terminus of human SHP-2, or a fusion containing a carboxy-terminal fragment of human PDGF receptor β protein.
Format	Liquid
Purity	Affinity purity

Target Information
Gene Description	Platelet derived growth factor family proteins form dimers that bind receptor tyrosine kinases PDGF receptor α and PDGF receptor β in a specific pattern. PDGFRβ homodimers bind PDGF BB and DD homodimers and the PDGF AB heterodimer. Heteromeric receptor PDGF α/β binds PDGF B, C, and D homodimers and the PDGF AB heterodimer. Ligand binding induces PDGF receptor dimerization and autophosphorylation, followed by binding and activation of cytoplasmic SH2 domain-containing signal transduction molecules, such as GRB2, Src, GAP, PI3 kinase, PLCγ, and NCK. Activated PDGF receptors initiate signaling pathways that control cell growth, actin reorganization, migration, and differentiation. PDGFRβ kinase-insert region residue Tyr751 forms the PI3 kinase docking site, and phosphorylation of PDGFRβ at this site inhibits the association between the SH2 domain of the PI3 kinase p85 subunit and PDGFRβ.SHP-2 is a nonreceptor protein tyrosine phosphatase that participates in signaling pathways that control cell growth, differentiation, migration, and death. Activation of SHP-2 and its association with Gab1 is critical for sustained Erk activation downstream of growth factor receptors and cytokines. Phosphorylation of SHP-2 at Tyr542 and Tyr580 in response to growth factor receptor activation is thought to relieve basal inhibition and stimulate SHP-2 tyrosine phosphatase activity.Insulin and various growth/survival factors activate Akt, a kinase that acts in a wortmannin-sensitive pathway involving PI3 kinase to help control survival and apoptosis. Akt is activated by phospholipid binding and activation loop phosphorylation at Thr308 by PDK1 and by phosphorylation within the carboxy terminus at Ser473.The p44/42 MAPK signaling pathway is activated in response to extracellular stimuli including mitogens, growth factors, and cytokines. Research suggests that this pathway is an important target in cancer diagnosis and treatment. External stimuli lead to activation of a kinase cascade that results in the activation of p44 and p42 by a MAP kinase. MEK1 and MEK2 activate p44 and p42 through phosphorylation of activation loop residues Thr202/Tyr204 and Thr185/Tyr187, respectively.Clinical studies describe PDGF expression in a number of different solid tumors, from glioblastomas to prostate carcinomas. The biological role of PDGF signaling in these tumors varies from autocrine stimulation of cancer cell growth to more subtle paracrine interactions involving adjacent stroma and even angiogenesis. Targeting PDGF signaling may be an effective way for tumor treatment.

Target Information

Gene Description

Platelet derived growth factor family proteins form dimers that bind receptor tyrosine kinases PDGF receptor α and PDGF receptor β in a specific pattern. PDGFRβ homodimers bind PDGF BB and DD homodimers and the PDGF AB heterodimer. Heteromeric receptor PDGF α/β binds PDGF B, C, and D homodimers and the PDGF AB heterodimer. Ligand binding induces PDGF receptor dimerization and autophosphorylation, followed by binding and activation of cytoplasmic SH2 domain-containing signal transduction molecules, such as GRB2, Src, GAP, PI3 kinase, PLCγ, and NCK. Activated PDGF receptors initiate signaling pathways that control cell growth, actin reorganization, migration, and differentiation. PDGFRβ kinase-insert region residue Tyr751 forms the PI3 kinase docking site, and phosphorylation of PDGFRβ at this site inhibits the association between the SH2 domain of the PI3 kinase p85 subunit and PDGFRβ.SHP-2 is a nonreceptor protein tyrosine phosphatase that participates in signaling pathways that control cell growth, differentiation, migration, and death. Activation of SHP-2 and its association with Gab1 is critical for sustained Erk activation downstream of growth factor receptors and cytokines. Phosphorylation of SHP-2 at Tyr542 and Tyr580 in response to growth factor receptor activation is thought to relieve basal inhibition and stimulate SHP-2 tyrosine phosphatase activity.Insulin and various growth/survival factors activate Akt, a kinase that acts in a wortmannin-sensitive pathway involving PI3 kinase to help control survival and apoptosis. Akt is activated by phospholipid binding and activation loop phosphorylation at Thr308 by PDK1 and by phosphorylation within the carboxy terminus at Ser473.The p44/42 MAPK signaling pathway is activated in response to extracellular stimuli including mitogens, growth factors, and cytokines. Research suggests that this pathway is an important target in cancer diagnosis and treatment. External stimuli lead to activation of a kinase cascade that results in the activation of p44 and p42 by a MAP kinase. MEK1 and MEK2 activate p44 and p42 through phosphorylation of activation loop residues Thr202/Tyr204 and Thr185/Tyr187, respectively.Clinical studies describe PDGF expression in a number of different solid tumors, from glioblastomas to prostate carcinomas. The biological role of PDGF signaling in these tumors varies from autocrine stimulation of cancer cell growth to more subtle paracrine interactions involving adjacent stroma and even angiogenesis. Targeting PDGF signaling may be an effective way for tumor treatment.

Shipping & Storage
Shipping	Shipped at 4 °C.
Storage Instructions	Store at +4 °C short term (1-2 weeks). Store at -20 °C long term.
Storage Buffer	Constituent: 100% PBS

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.